Travere Therapeutics Posts Q1 Sales Surge 64% to $124.5M with FSGS Approval
Travere Therapeutics reported first-quarter net product sales of $124.5 million, up 64% from $75.9 million year-over-year, driven by FILSPARI demand. The company logged a net loss of $37.1 million ($0.40 per share) versus $41.2 million a year earlier, while non-GAAP net income reached $4.1 million ($0.05 per share).
1. First Quarter Financial Results
Travere reported net product sales of $124.5 million in Q1 2026, a 64% increase from $75.9 million in Q1 2025, driven by FILSPARI demand. Net loss narrowed to $37.1 million ($0.40 per share) from $41.2 million ($0.47), while non-GAAP net income was $4.1 million ($0.05).
2. FILSPARI Performance and FSGS Approval
U.S. FILSPARI net sales reached $105.2 million, up 88% year-over-year, with 993 new patient starts for IgA nephropathy. On April 13, FDA approved FILSPARI for focal segmental glomerulosclerosis in patients aged 8 and older, targeting over 30,000 U.S. patients without nephrotic syndrome.
3. Pipeline Advancement
The Phase 3 HARMONY study of pegtibatinase for classical homocystinuria resumed enrollment and dosed its first patient, with topline data expected in second half 2027. Travere held $264.7 million in cash, equivalents and marketable securities as of March 31, 2026, excluding a $25 million milestone received in April.